SeleXel Overview

  • Founded
  • 2006
Founded
  • Status
  • Private
  • Latest Deal Type
  • Angel
  • Latest Deal Amount
  • $469K
Latest Deal Amount
  • Investors
  • 1

SeleXel General Information

Description

Developer of biotech solutions intended to treat invasive or metastatic cancers. The company develops a portfolio of molecules based on the RNA interference technology that inhibit very specifically the production of a protein playing a key role in the development or progression of cancer, enabling healthcare professionals to restore the ability of the immune system to eliminate the tumor.

Contact Information

Website
www.selexel.com
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Primary Office
  • Centre Pierre Potier
  • 1 place Pierre Potier Oncopole input B
  • 31100 Toulouse
  • France
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

SeleXel Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Angel (individual) 14-Dec-2017 $469K 00.000 00.000 Completed Startup
2. Angel (individual) 27-Jan-2014 00000 00000 00.000 Completed Startup
1. Accelerator/Incubator Completed Generating Revenue
To view SeleXel’s complete valuation and funding history, request access »

SeleXel Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000 0000.00 0000.00 00 0000.00 0.000
Ordinary 000 0000.00 0000.00 00 0000.00 0.000
Ordinary 000 0000.00 0000.00 00 0000.00 0.000
Ordinary 796 $472.82 $472.82 1x $472.82 5.12%
Ordinary 430 $443.27 $443.27 1x $443.27 2.77%
To view SeleXel’s complete cap table history, request access »

SeleXel Patents

SeleXel Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
FR-3058062-A1 New use of a double stranded oligonucleotide Pending 27-Oct-2016 00000000000 0

SeleXel Executive Team (3)

Name Title Board Seat Contact Info
Pierre Attali MD Co-Founder & President
Florence Cabon Co-Founder
You’re viewing 2 of 3 executive team members. Get the full list »

SeleXel Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Agoranov Accelerator/Incubator 000 0000 000000 0
To view SeleXel’s complete investors history, request access »